reVision Therapeutics, focused on repurposed drugs for the treatment of ophthalmic diseases, was selected for the Audience Choice award at the BIO-Europe 2018 Startup Slam. President and CEO Paul Fehlner explains his company’s need for seed money to develop their very strong Phase III candidate as well as investment for the early trials of two rare disease candidates to accelerate treatments to those with a variety of eye diseases needing better therapies.
BIO-Europe® 2018 Interviews
reVision Therapeutics on potential fast path for drugs treating rare eye diseases
